ESMO Asia 2015: Cancer Drives Patients to Poverty in Southeast Asia
Five percent of cancer patients and their families were pushed into poverty in Southeast Asia between March 2012 and September 2013 because of high disease-related costs, a study (Abstract 52O) by Bhoo-Pathy et al at the European Society for Medical Oncology (ESMO) Asia 2015 Congress in Singapore showed.
Study Findings
The research, conducted earlier this year, evaluated data collected in eight low- and middle-income Southeast Asian countries (Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, and Vietnam) to assess patient risk of financial catastrophe (medical expenditures exceeding 30% of annual household income), economic hardship (inability to make necessary household payments) and impoverishment (living on less than U.S.$2 per day), and the association between economic struggles and risk of death. The study showed that cancer resulted in “financial catastrophe” for almost half of the patients who suffered from economic hardship at the time of diagnosis.
Out-of-pocket health-care expenditure could have a direct or indirect negative impact on patient’s life, potentially affecting quality of life, compliance, and risk of death. According to study results, up to 20% of patients did not attend their medical appointments or could not pay for medicines. Disadvantaged patients had an 80% higher risk of death within 12 months following diagnosis compared to their counterparts without economic difficulties at baseline.
Commenting on the study, Christoph Zielinski, MD, of the Medical University of Vienna said: “Cancer places a significant financial burden on patients, even in middle- and high-income countries. It is therefore no surprise that patients in low and middle-income countries face a relatively larger burden upon their diagnosis. While early detection of cancer can somewhat alleviate this financial burden, patients are still in a precarious situation and are at risk of financial catastrophe. Cancer can be an even more terrible disease for poor or socially underprivileged people, and cancer treatment costs constitute only a portion of the problem."
He continued, "Cancer is also linked to morbidity resulting from treatment side effects, evolvement of the underlying disease, resulting in the inability to follow basic tasks of daily life requiring support by the immediate surroundings, and even terminally severe restrictions in work abilities. Some or many of these aspects can be neutralized by appropriate social programs, albeit lots of problems remain or become only slightly alleviated by even the best of social systems.”
“Cancer stage explained most of the financial catastrophic risk and premature deaths observed in the study,” said study senior author Nirmala Bhoo-Pathy, MD, PhD, of the Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. “However, low-income patients remained financially vulnerable, even when diagnosed at very early cancer stages. There appeared to be missed opportunities for surgery in patients with operable malignancies, particularly in low-income groups. Patients without health insurance also remained at higher risk of incurring catastrophic expenditures and dying, even in early stages”.
The World Health Organization (WHO) reports 1.7 million new cancer cases every year in Southeast Asia, and the prevalence of cancer mortality is expected to be up to 45% higher in 2030.
Strategies for Improvement
Strategies to limit the negative financial impact on cancer patients from low- and middle-income countries should be a priority, as are strategies for treating the disease. Many would be feasible options, according to Tikki Pang, PhD, of the National University of Singapore.
“Screening programs for early detection is a proven strategy in many countries to reduce cancer-related direct and indirect costs, as well as education and awareness raising among the population,” Dr. Pang said. “Innovative health insurance models, eg, a mix of public and private, may also be a useful strategy, but each country must decide what scheme suits them best. Another strategy could be promoting the production of generics at the national or regional level.”
“Our study provides health authorities with significant data to enable them to priorities cost-effective strategies in cancer control,” Dr. Bhoo-Pathy said. “Early detection may provide the best avenue to favorably influence economic and disease outcomes in cancer patients from low- and middle-income Southeast Asian countries, followed by increasing accessibility to effective treatments and provision of financial risk protection. The health financing systems in these countries also require re-examination to ensure that public funds are directed to patients who need them the most.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
